In conclusion, p53, as a proven immunotherapeutic target in ovarian cancer, plays an important role in the development, progression, and immunotherapy of ovarian cancer and can be modulated by ubiquitination and deubiquitination modifications (Fig. 5B). This evidence concerns the gene TP53 and ovarian cancer.